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PEG4000 modified liposomes enhance the solubility of quercetin and improve the
liposome functionality: in vitro characterization and the cellular efficacy
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Abstract: Quercetin, a multifunctional therapeutic agent, is used in various types of cancer. However, its therapeutic effect is limited by
virtue of poorly aqueous solubility and instability in the physiological medium. To overcome these limitations, we aimed (i) to design
quercetin loaded liposomes with unlinked-PEG4000 with regard to not only surface modification but also solubility enhancement,
and (ii) to investigate the antineoplastic effects on HeLa cells. PEG4000 increased the quercetin solubility 2.2 fold. PEG4000 modified
liposomes displayed small particle size (254 ± 69 nm), low polydispersity index (0.236 ± 0.018), favorable zeta potential (–35.4 ± 0.6
mV), high quercetin encapsulation efficiency (87.6 ± 5.6%), and drug loading (22.2 ± 6.9%). The homogeneity and particle size of stable
PEGylated liposomes were proved by transmission electron microscopy. The drug release was reached up to 65.1 ± 3.8% in 6 h. The
IC50 value of quercetin loaded PEGylated liposomes was 16.3 μg/mL on HeLa cells, while that of quercetin was 88.3 μg/mL. PEGylated
liposomes remarkably hampered the adherence and colony formation ability of cells according to crystal violet staining tests. The
convenience of PEGylated liposomes for the parenteral application was stated by the hemolysis assay. The high-throughput screening
assays based on AO/PI staining proved the drastic decrease of viable cell count. Moreover, qPCR tests based on gene expression levels
revealed that the quercetin loaded PEGylated liposomes treatment could be more effective than free quercetin on the mitochondrial
apoptosis of HeLa cells. These promising results allow considering further in vivo studies for efficient cancer treatment with quercetin
loaded PEG4000 modified liposomes.
Key words: Quercetin, solubility, PEGylated liposomes, drug delivery, antitumoral effect, mitochondrial apoptosis

1. Introduction
Quercetin (QC) is a versatile therapeutic agent with antioxidant, antihypertensive, antithrombotic, angioprotective, and
antiinflammatory effects, and also used for preventing obesity-related diseases, as well as to treat some kinds of cancer
[1]. By having these properties, it has gained widespread attention for various potential applications in the healthcare
industry. However, its poorly aqueous solubility, instability in the physiological medium, and low bioavailability remain
as main obstacles in using QC in the pharmaceutical field [2]. The water solubility of quercetin is quite low, 1.53–12.5
mg/L at gastrointestinal pH levels (pH 2–7) [3], and so there have been many attempts to alleviate this fundamental
problem with the help of cosolvent effect, surfactant effect, inclusion complex or nanosized drug delivery systems. In
one of these applications, DMSO was used to dissolve QC, but such concerns as the requirement of higher doses, the
occurrence of dose-dependent hemolysis, and unpleasant odor hampered the DMSO usage [4]. Apart from DMSO, adding
propylene glycol into the solvent systems also increased the solubility of QC [5]. Cosolvent effects might enhance the
solubility, but not alter the instability of QC in the physiological medium. Therefore, developing the new dosage forms of
QC with increased solubility and improved in vivo stability is highly needed. In this particular case, the importance of QC
encapsulation cannot be neglected. It was reported that nanoencapsulation enhances the solubility and pharmacokinetics
profiles of insoluble drugs [6]. Thus, extensive efforts related to inclusion complexes, prodrugs, nanocrystals, polymeric
nanoparticles, microparticulates, magnetic nanoparticles have been made [7–11]. Among drug carrier systems, lipidbased systems take a step forward since the presence of fat in formulation increases the QC bioavailability [5, 12].
Liposomes which are the lipid-based systems are selfassembled lipid bilayer structures with phospholipid and
cholesterol components. The size of these nearly spherical lipid vesicles can usually range between 50 and 450 nm for
* Correspondence: Melike.Demirbolat@acibadem.edu.tr
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medical application [13]. Liposomes have good compatibility because they are nontoxic, nonimmunogenic, and completely
biodegradable. They increase efficacy, stability, and function for a long time and reduce the encapsulated agent’s toxicity
[14]. The physiobiochemical characteristics of liposomes can be tailored by altering the types and ratios of component
and decorating the liposomal surface with biocompatible hydrophilic polymers like polyethylene glycol (PEG) [15]. Using
PEGs with different molecular weights on liposome surface, also known as PEGylation, provides a shielding effect for
enzymes to access lipid vesicles due to stealth properties of PEG chain [16]. These modifications can give drastic effects
especially on biological environment as liposomes recognition of opsonins and liposomal clearance by the mononuclear
phagocyte system slow down and liposome circulation time extends [17,18]. In briefly, PEGylation positively affects on the
stability, passive targeting ability to tumoral tissues, circulation time, therapeutic effects and reduction of the toxicity of
encapsulated drug [19]. Therefore, the entrapment of hydrophobic QC in these stealth liposomes can be a feasible strategy
to overcome its poor solubility in aqueous medium, in other terms, the main challenges of QC formulation.
In this study, we developed QC-loaded PEGylated liposomes and explored the effect of their apoptotic activity in
cell cultures, comparing to QC-loaded unmodified liposomes. Stable QC loaded stealth liposomes with small size and
high encapsulation efficiency were suitably produced for parenteral administration. Even when used at minimal doses,
they augmented their anticancer efficacy on cervical cancer cells in cell viability, colony formation, cell staining and gene
expression.
2. Materials and methods
2.1. Materials
Quercetin (≥95% HPLC), L-α-phosphatidylcholine (≥99%, egg yolk, lyophilized powder), cholesterol, PEG2000, and
PEG4000 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Phosphate buffered saline (PBS) tablets were obtained
from BioShop (Ontario, Canada). The cervical cancer cells (HeLa) were obtained from ATCC (Manassas, VA, USA).
Dulbecco’s modified Eagle’s medium (DMEM), MTT (3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide),
Bax, Bcl-2, and GAPDH primers were purchased from Invitrogen (Thermo Fisher Scientific, USA). All other reagents
were of analytical grade.
2.2. Solubility of QC
The solubility of QC was evaluated in distilled water, in PEG2000 aqueous solution and in PEG4000 aqueous solution
to investigate the effect of molecular weight of PEG as a surface coating material on the solubility of QC. To this end, an
excess amount of QC was added to 10 mL of distilled water and mixed with PEG2000 or PEG4000. Then, the mixtures
were stirred at 1000 rpm using a magnetic stirrer for 48 h. Then, the dispersion was filtered through a membrane filter
(0.22 μm). The completely dissolved amount of QC was analyzed via double beam UV-VIS spectrophotometer (Shanghai
Mapada Instruments UV-6100, China) [20,21]. Briefly, certain amount of QC was dissolved in methanol, and a series of
QC samples at different concentrations were analyzed. The linear calibration curve was obtained in the range of 0.2–14
μg/mL for QC.
2.3. Preparation of liposomes
PEGylated liposomes encapsulating quercetin were prepared by thin film hydration method [4]. L-α-phosphatidylcholine,
cholesterol, quercetin and PEG4000 were dissolved in chloroform and methanol (3:1, v/v) in a round bottom flask. The
organic solvent was evaporated under reduced pressure at 50 rpm for 4 h at 60 °C on a rotary evaporator (Buchi Rotavapor
R100). After the obtained thin film was remained overnight in a vacuum oven at room temperature for removal of residual
organic solvent, it was rehydrated 10 mL of phosphate buffer saline (PBS, pH: 7.4). The mixture was subsequently vortexed
for 5 min and sonicated for 10 min. The liposomes were subjected to the centrifugation at 14,000 g for 1 h to remove any
unentrapped quercetin. The precipitates were suspended with PBS. Other produced liposomes (LQ1: quercetin loaded
non-PEGylated liposomes; L1 and L2; non-PEGylated and PEGylated quercetin-free formulations, respectively) were
prepared following the same procedure without using quercetin and/or PEG in the process. The compositions of liposomes
were given in Table.
2.4. Characterization of liposomes
2.4.1. Particle size and zeta potential measurements
The particle size (PS), and polydispersity index (PDI) of liposomes were measured by dynamic light scattering (DLS) using
Litesizer 100 (Anton Paar, Austria). The scattering data were recorded at a 90° angle. The zeta potential (ZP) of them were
measured with the same device by applying laser Doppler velocimetry (LDV). The dispersions were diluted more than a
hundred times with PBS and analyzed six times.
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Table. The compositions of liposomes.
Formulation

L1

L2

LQ1

LQ2

L-α-phosphatidylcholine

6 mM

6 mM

6 mM

6 mM

Cholesterol

3.4 mM

3.4 mM

3.4 mM

3.4 mM

PEG4000

-

0.08 mM

-

0.08 mM

Quercetin

-

-

6.6 mM

6.6 mM

2.4.2. The morphological investigation
QC loaded liposomes (LQ1 and LQ2) were visualized with Thermo Scientific Talos L120C transmission electron
microscope (Thermo Fisher Scientific, Massachusetts, USA). A sufficient quantity of samples was deposited on a carbon
coated TEM copper grid and allow to dry in air at room temperature to form thin films. TEM images were taken at suitable
magnifications after the grid insertion in TEM.
2.4.3. Encapsulation efficiency and drug loading capacity
The amount of quercetin entrapped in liposomes was determined through the indirect method based on the measurement
of the drug present in the external phase [22]. After the centrifugation process in the liposomes preparation, the supernatant
containing free drug was analyzed for the drug content via double beam UV-VIS spectrophotometer (Shanghai Mapada
Instruments UV-6100, China) at 268 nm and 375 nm where the quercetin exhibits two major absorption peaks [23].
Although the absorbance values at both wavelengths were recorded, data collected at 268 nm was used in all calculations
due to high consistency. The amount of QC was calculated using the previously subtracting calibration curve. The
percentage of drug encapsulation in liposomes
and#&"'(!
drug loading
capacity")of)+..
liposomes
were calculated with the following
!"!#$
") *+',-#&"'(!
*+',
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸
𝑒𝑒𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 (𝐸𝐸𝐸𝐸) % =
𝑥𝑥100,
equations
[24]:
!"!#$ #&"'(! ") *+',

𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑒𝑒𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 (𝐸𝐸𝐸𝐸) % =

!"!#$ #&"'(! ") *+',-#&"'(! ") )+.. *+',
!"!#$ #&"'(! ") *+',

𝑥𝑥100,

𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 − 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
𝑥𝑥100.
𝑡𝑡𝑜𝑜𝑡𝑡𝑡𝑡𝑡𝑡 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 − 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙was
(𝐷𝐷𝐷𝐷)
% = insoluble in water and the small volume of sample𝑥𝑥100.
The
quercetin
practically
in centrifugation may be insufficient
𝑡𝑡𝑜𝑜𝑡𝑡𝑡𝑡𝑡𝑡 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙
for dissolving quercetin. To crosscheck this method, the encapsulation efficiency and the drug loading studies were also
replicated using dialysis bag
[25]. One milliliter
/01 (1#&3$.)-/01
(0$#(5) of liposome dispersion (not to be centrifuged) was placed in a dialysis bag
% 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶
𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣
× 100.
(MWCO
12kDa).
The=
dialysis
bag
including
sample
was put into the beaker including 200 mL of PBS (pH 7.4). It was kept
(6"(!+"$)
/01
-/01 (0$#(5)
under stirring at 500 rpm/01
for(1#&3$.)-/01
24 h. After (0$#(5)
dialysis, 1 mL of sample was withdrawn and analyzed. The calculation was done
% 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶to𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣
= /01 (6"(!+"$)
× 100.
according
the abovementioned
formula.
-/01 (0$#(5)
/01 (1#&3$.)-/01 (- 6"(!+"$)
× 100.
2.5.%
In𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻
vitro release=studies
/01 (7 6"(!+"$)-/01 (- 6"(!+"$)
Quercetin release from/01
liposomes
were(-performed
using the dialysis bag method [26]. After the centrifugation, 500 μL of
(1#&3$.)-/01
6"(!+"$)
% 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻
= /01
× 100.
liposomes
were placed
into
the dialysis (bag
(MWCO
12kDa) following the redispersion of the precipitates with 1 mL of
(7 6"(!+"$)-/01
6"(!+"$)
PBS (pH 7.4). The study conditions were set at a stirring speed of 50 rpm, dissolution medium volume 100 mL PBS (pH
7.4) at 37 °C. The samples were withdrawn at predetermined time intervals (10th, 15th and 30th min, and 1st, 2nd, 4th, 6th,
and 24th h) to determine the drug amount and replenished with the same medium volume. Experiments were repeated
three times. The samples were analyzed spectrophotometrically at 268 nm and 375 nm and expressed as a percentage of
the drug release.
2.6. Cell viability assay
HeLa human cervical cancer cell lines were used in this study. Cells were cultured in DMEM medium supplemented with
10% fetal bovine serum FBS, 100 U/mL penicillin and 100 μg/mL streptomycin and 2 mM L-glutamine. The cultures were
incubated at 37 °C in a humidified atmosphere with 5% CO2. The culture medium was replaced with fresh medium every
2 days until reaching suitable confluency of about 90%. All reagents and medium for cell culture studies were purchased
from Gibco Company. All experiments were repeated triplicate (n = 3).
The cells except the control cells were treated with different concentrations (1–1000 μg/mL) of quercetin and produced
liposomes, all wells were incubated for 12 h, and then washed with PBS and added to 100 μL DMEM. For MTT assay, ten
microliters of the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Vybrant, Invitrogen) labelling
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 (𝐷𝐷𝐷𝐷) % =

1013

𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑒𝑒𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 (𝐸𝐸𝐸𝐸) % =

!"!#$ #&"'(! ") *+',-#&"'(! ") )+.. *+',
!"!#$ #&"'(! ") *+',

DEMİRBOLAT et al. / Turk J Chem

𝑥𝑥100,

𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 − 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 37 °C incubator with 5% CO in air.
reagent
was
added to
these
2
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙
(𝐷𝐷𝐷𝐷)
% wells
= and incubated for 4 h in humidified atmosphere at𝑥𝑥100.
𝑡𝑡𝑜𝑜𝑡𝑡𝑡𝑡𝑡𝑡was
𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙
After the incubation, 100 μL of the SDS buffer
added𝑜𝑜𝑜𝑜
into
each well for solubilization of formazan precipitate. Then
absorbance was measured by microplate reader at 570 nm (Epoch, Biotek, USA) and was carried out in triplicate of each
assay. Cell viability was calculated as follows [27]:
/01 (1#&3$.)-/01 (0$#(5)

% 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 = /01 (6"(!+"$) -/01 (0$#(5) × 100.

At the same time, images of HeLa cells before and after treatment of quercetin and produced liposomes were also
/01 (1#&3$.)-/01 (- 6"(!+"$)
assessed
by inverted=microscope
attached to camera
system (Zeiss Axioivert, Germany).
% 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻
× 100.
/01 (7 6"(!+"$)-/01 (- 6"(!+"$)
2.7. Colony formation assay
For evaluating colony formation, HeLa cells seeded in twelve well plates (500 cells per well) were treated with quercetin
and produced liposomes (10 μg/mL), and cultured
in a growth
medium for
days.
The medium was refreshed every three
!"!#$ #&"'(!
") *+',-#&"'(!
")14
)+..
*+',
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑒𝑒𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 (𝐸𝐸𝐸𝐸) % =
𝑥𝑥100,
!"!#$ #&"'(!
*+',
days until incubation was completed. At the end of incubation,
each")
well
in the plate was washed with PBS, fixed with cold
methanol/acetic acid, stained with 0.5% crystal violet staining solution for 15 min and washed with dH2O, respectively.
The stained cells were examined with microscope (Zeiss Axioivert, Germany). The number of colonies in each well was
counted and analyzed [28].
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 − 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
2.8.𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
Hemolysis
assay
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙
(𝐷𝐷𝐷𝐷) % =
𝑥𝑥100.
𝑡𝑡𝑜𝑜𝑡𝑡𝑡𝑡𝑡𝑡tubes
𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎
𝑜𝑜𝑜𝑜 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙
The freshly obtained blood sample was put into
involving
EDTA and centrifuged at 1000 g for 15 min. After discarding

the supernatant, 10% (w/v) RBC solution was prepared with pellet in PBS (pH 7.4). A total of 100 μL RBC solution and 900
μL quercetin and produced liposomes at the concentration of 10 μg/mL were mixed in Eppendorf and then were incubated
at 37 °C for 1 h. Besides 900
0.9% NaCl(0$#(5)
and dH2O were respectively used for negative and positive control. The mixtures
(1#&3$.)-/01
/01μL
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣
= /01
× 100.
were%centrifuged
at 1000
g for
15
min
following
(6"(!+"$) -/01 (0$#(5)incubation and supernatants were spectrophotometrically measured at 540
nm [29]. The experiments were repeated three times. The percentage of hemolysis was calculated as follows:
/01 (1#&3$.)-/01 (- 6"(!+"$)

% 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 = /01 (7 6"(!+"$)-/01 (- 6"(!+"$) × 100.

According to this formula, the negative control was accepted as blank.
2.9. AO/PI staining
Propidium iodide (PI) and acridine orange (AO) double staining in cultured HeLa cells were measured to detect apoptosis
after the treatment of quercetin and produced liposomes, as previously described [28]. Cells (1 × 104) were cultured in
a twelve-well plate and treated with quercetin and produced liposomes (10 μg/mL). After a 12-h incubation, cells were
washed with PBS and stained with AO (1 µg/mL) and propidium iodide (1 µg/mL) for 10 min. After discarding the excess
dye by washing with PBS repeatedly, images of cells were captured under a fluorescence microscope (Zeiss Axioivert,
Germany).
2.10. qPCR for gene expression
Total RNA was extracted from 5 × 106 HeLa cells, according to the manufacturer’s instructions (Invitrogen), as previously
described [30]. A total of 1 μg RNA was reverse transcribed as the template for cDNA synthesis using high capacity cDNA
Reverse Transcription Kit (Applied Biosytem) according to the manufacturer’s instructions. Quantitative real-time PCR was
performed for Bax, Bcl-2 and GAPDH using primers. The primers sequence was: Bax: 5’ – GCCCTTTTGCTTCAGGGTTT
- 3’(forward),5’ – TCCAATGTCCAGCCCATGAT - 3’(reverse); Bcl - 2: 5’ – GACAGAAGATCATGCCGTCC - 3’
(forward), 5’ – GGTACCAATGGCACTTCAAG - 3’(reverse); GAPDH: 5′ - AGGGCTGCTTTTAACTCTGT - 3′(forward),
5′ - CCCCACTTGATTTTGGAGGA - 3’(reverse). One hundred nanograms of cDNA was amplified using SYBR Green
PCR Master Mix (Applied Biosytem) on the ABI StepOnePlus detection system, programmed for initial denaturation step,
95 °C for 10 min followed by 40 cycles of denaturation at 95 °C for 15 s; annealing, 1 min at 60 °C; and elongation, 10 s at
72 °C. The amplification results were analyzed using StepOne Software v2.3 (Applied Biosystems, Foster City, CA) and the
genes of interest were normalized to the corresponding GAPDH results. Data were expressed as fold induction relative to
the control.
2.11. Statistical analysis
All experiments were carried out in triplicate and values were expressed as mean ± SD. Statistically significant differences
were determined using One-way ANOVA followed by Tukey’s multiple comparison test. Statistically significant differences
in all cases were defined as a p-value of < 0.05.
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3. Results and discussion
3.1. Solubility of QC
The QC solubility test results in various media as pure distilled water and PEG2000 or PEG4000 aqueous solution are
presented in Figure 1. The aqueous solubility of anhydrous quercetin was found 1.53 ± 0.27 µg/mL which is in agreement
with the value given in the literature [3,31]. Solubilization with surfactants is one of the various techniques to enhance
the drug solubility [32]. Adding PEG, a nonionic surfactant, into the solution increased the QC solubility in water, as
predictably. PEG2000 increased 1.5-fold of its solubility while 2.2-fold increment occurred in PEG4000 solution. The
surfactant molecular weight has a noticeable influence on the drug solubility and the higher molecular weight resulted in
the higher solubility. It was also reported that increasing the PEG molecular weight created the better hydrophilicity and
water solubility, and increased drug solubility [33]. PEG4000 was used in liposome formulation since it provided better
QC solubility.
3.2. Particle size and zeta potential measurements
One of the crucial parameters for the characterization of nanocarriers is particle size due to their effect on in vitro
behavior and stability, in vivo integrity, retention, cell penetration and consequently intestinal absorption. It is widely
known that smaller particles have a greater surface area that ensures convenient solubility. Besides, they might facilitate
passive targeting. It is generally accepted that the optimum size is lower than 500 nm for cancer treatment, particularly
[34–36]. The particle sizes of produced liposomes were given as hydrodynamic diameter in Figure 2a.
As shown, the particle sizes were varied within the range of 74 ± 14 and 254 ± 69 nm. Although adding polyethylene
glycol to liposome structure did not make significant differences in the particle size, it was significantly increased when
quercetin was added to the formulations. Two earthly reasons could be stated; (i) the small amount (0.08 mM) of PEG4000
was used in formulations comparing to the amount of quercetin (6.6 mM), (ii) quercetin might have a large surface area
due to its cyclic compound while PEG4000 is the straight chain.
The polydispersity index (PDI) is a factor that reflects the particle size distribution and is used to evaluate the colloidal
stability of liposomes. The PDI close to 0 implicates the degree of uniformity, while the PDI values higher than 0.4 implicates
the heterogeneity, in other words highly polydisperse systems. The PDI’s outstanding value for liposomes indicating a
homogenous distribution is considered as 0.3 and below [37, 38]. The PDI of liposomes was < 0.3 of PDI, indicating that
they were monodisperse (Figure 2a).
Besides particle size and polydispersity index, the zeta potential plays an essential role in in vitro and in vivo stability.
The particles with higher values than ± 30mV are less prone to aggregation or fusion. Moreover, negatively charged
liposomes are less phagocytized than positive ones [15,39]. The zeta potentials of liposomes were higher than 30 mV and
negatively charged (Figure 2b). These findings implied the positive effects of produced liposomes on stability.
3.3. The morphological investigation
TEM images of liposomes were monitored (Figures 3a–3d for QC loaded liposomes, and Figures 4a–4d for QC loaded
PEGylated liposomes). TEM images confirmed spherical geometry and the practically monodispersion of prepared
samples. Comparing images of liposomes, it was obvious that PEGylation provided the occurrence of more spherical,
stable particles and hampered the aggregation tendency of lipids.

Figure 1. Solubility of QC in distilled water, PEG
2000 and PEG 4000.
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Figure 2. Characterization of liposomes with or without quercetin; a. particle size (bar graph) and polydispersity index
(scatter plot) measurement results, b. zeta potential results.

Figure 3. TEM images of quercetin loaded liposomes with different magnifications. Scale bars: A: 500 nm, B: 200
nm, C: 100 nm, and D: 50 nm.
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Figure 4. TEM images of quercetin loaded PEGylated liposomes with different magnifications. Scale bars: A:
500 nm, B: 200 nm, C: 100 nm, and D: 50 nm.

3.4. Encapsulation efficiency and drug loading capacity
The quercetin encapsulation of liposomes was evaluated by UV-VIS spectroscopy according to two indirect methods;
centrifugation and dialysis. Centrifugation is mostly preferable method since it is time-saving, easy to apply and both
fractions can be kept. However, drugs could be trapped in precipitate in some cases, particularly poorly water-soluble
drugs. After centrifugation, a washing process should be done to remove the free drug. That is tricky because of the small
volume of diluent. In case of poor separation of free drug from nanocarriers in centrifugation, dialysis bag method was
also performed. In this method, higher volume of medium is quite enough to make quercetin soluble. The percentages of
EE and DL of quercetin were given in Figure 5.
The EE and DL measurements based on centrifugation were 65.9 ± 4.7% and 17.5 ± 6.0% for quercetin in liposomes,
respectively. PEGylation step increased the amount of QC in liposomes up to 87.6 ± 5.6% for EE and 22.2 ± 6.9% for
DL. These results could be accounted for by the solubility increasing of QC as a consequence of the surfactant effect of
PEG4000. In the dialysis method, similar results were obtained and there were no significant differences between two
methods.
3.5. In vitro release studies
Quercetin release from liposomes were performed through the dialysis bag method [40]. The in vitro release profiles of
quercetin loaded liposomes were shown in Figure 6.
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Figure 5. The encapsulation efficiency and drug loading capacity of
liposomes with or without PEG coating (LQ1 and LQ2) based on
centrifugation or dialysis technique.

Figure 6. The release profile of quercetin from liposomes (LQ1 and
LQ2). The embedded figure which was placed in right below focused
the quercetin release on the first 1 hour.

The quercetin release from LQ1 liposomes was reached 25.8 ± 4.7% in 1 h (the embedded figure focused on the first 1
hour) while that from LQ2 liposomes were 54.5 ± 1.5%. Since PEG is a hydrophilic polymer, the PEGylation of liposomes
might aid the release of quercetin from liposomes. The release was completed in 6 h for both formulations and the total
release of QC from LQ2 liposomes was 65.1 ± 3.8%. Not having the 100% of release could be related to the high affinity
between lipophilic quercetin and lipophilic nanocarriers.
3.6. Cell viability assay
Quercetin and all produced liposomes were applied to HeLa cells for 12 hours of incubation. Untreated cells were used as a
control representing 100% viability. L1 and L2 (quercetin-free liposomes with and without PEG, respectively) were chosen
as negative control groups so that the phospholipid effect, and consequently the physiological tolerability of liposome
formulations could be taken into consideration. Phospholipids and sterols like cholesterol are major components of all cell
membranes, as well as liposomes. They provide the appropriate structural organization of the membrane bilayer and affect
cellular functions like permeability and fluidity [41]. Empty liposomes, L1 and L2, did not cause significant cell death (seen
in Figure 7a). There were no statistical differences between control groups and quercetin-free liposomes at low doses, while
they showed approximately 80% of cell viability even at their quite high concentration (1 mg/mL). Quercetin showed a
concentration-dependent manner on cell survival in the range of 1–1000 μM of concentration. It decreased cell viability
from 68% to 57% when increasing its concentration from 10 μg/mL to 100 μg/mL. The IC50 values were found as 88.3
μg/mL for quercetin, 8.1 μg/mL for LQ1, and 16.3 μg/mL for LQ2 in HeLa cells. IC50 value of quercetin was 88.3 μg/mL,
which was consistent with previous study [42,43]. Liposomes decreased the IC50 values of quercetin five times compared
to LQ2 and 10 times compared to LQ1. It was reported that IC 50 values of quercetin loaded stealth liposomes (with

1018

DEMİRBOLAT et al. / Turk J Chem

Figure 7. (a) Comparison of cytotoxicity between quercetin and produced liposomes at the concentration of 1–1000 μg/mL, (b)
Morphological changes of samples in HeLa cells 8 h and 12 h after treatment. Cellular morphology was observed and captured at 20×
magnification using an inverted microscope (c) Colony formation assay in HeLa cells. Cells were treated with 10 μg/mL quercetin and
produced liposomes and were cultured for 14 days and were stained with crystal violet. Colonies shown as overview images (up) and
detailed images individual colony (down) d) Colony formation ratios were quantitated compared to control groups (**p < 0.01, ***p <
0.001 compared to control in HeLa cells).

PEG2000) in HeLa cells was 184 μM (equal to 55.8 μg/mL) after 24 h incubation [43]. In this regard, it can be concluded
that a much higher therapeutic effect has been achieved with PEGylated liposomal formulations.
On the other hand, a reduction in cell viability of more than 50% was achieved approximately at a dose of 10 μg/mL for
LQ1 and LQ2. These results suggest that liposomal quercetin formulations demonstrated a much higher cytotoxic effect
on HeLa cells when compared to free quercetin regardless of the presence of PEGylation. However, the effect of quercetin
loaded PEGylated liposomes (LQ2) on cell viability became more pronounced at the higher concentration (above 10 μg/
mL). After the treatment with the LQ2 formulation at a concentration of 100 μg/mL, the percentage of the surviving cells
was 18.0 ± 2.1.
To confirm the MTT results, the morphological changes were investigated by induced by 10 μg/mL of quercetin or
produced liposomes with the same concentration. As seen in Figure 7b, L1 and L2 maintained the regular morphology of
HeLa cells. There was no significant decrease in viability of the cells like what was observed with the control group. When
cells were treated with quercetin, the HeLa cells became round in shape and smaller in size. The number of viable cells and
morphological change was quite apparent after LQ1 and LQ2 treatment. The number of living cells was decreased after the
L1Q exposure. Moreover, LQ2 caused a significant change in the morphology of HeLa cells with a strong reduction in cell
viability. We can conclude that the cytotoxic action of quercetin was boosted in liposomes formulation. On the other hand,
no significant decrease in viability of the cells was observed between 8 h-incubation and 12 h-incubation. The possible
explanation of it might be related to drug release which was completed at 6 h in L1Q and L2Q formulations.
3.7. Colony formation assay
Firstly, we examined the effects of quercetin or produced liposomes on the colony formation ability of HeLa cells. As
shown in Figure 7c, when we exposed HeLa cells to quercetin, L1Q and L2Q the number of colony reduced. Mainly in 10
μg/mL doses of L1Q and L2Q, colonies development drastically decreased by 79% and 85%, respectively, compared to the
control group (Figure 7d).
3.8. Hemolysis assay
To investigate the safety of produced liposomes and suitability for parenteral use, hemolysis rate of compounds was
evaluated, as shown in Figure 8. Hemolysis is defined as a rupture of red blood cells with the release of hemoglobin and
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Figure 8. Hemolysis rate (%) after 1 h of incubation at 37 °C with
quercetin and all produced liposomes at the concentration of 10
μg/mL. Each value represents the mean and SD (n = 3), ***p <
0.001.

other intracellular contents into the plasma [44]. Nonaqueous formulations are known to cause hemolysis. Therefore,
evaluating the hemolytic potential of a parenteral formulation is crucial [45]. NaCI, a fully biocompatible agent whose
parenteral usage cannot cause hemolysis, was used as a negative control group while dH2O, a hemolytic agent, was used
as a positive control group. The hemolytic rate of NaCI was 5% and that of dH2O was 100%, as expected. Quercetin
showed hemolysis of 41%. Generally, hemolysis value of nonhemolytic compounds is below 10% while values above 25%
are considered hemolytic [45]. Therefore, quercetin could be considered as a hemolytic agent. The exclusively liposomal
formulations of quercetin (LQ1) could not sufficiently improve its potential destructive effect on erythrocyte. Quercetinfree formulation (L1) with lipid structure also caused moderately hemolysis (28%). On the other hand, PEGylation
were significantly decreased <10% hemolysis of erythrocytes (8% and 10% for L2 and LQ2, respectively). The presence
of polyethylene glycol groups in formulation can conceal the surface of liposomes, and consequently the inhibition of
hydrophobic interaction occurs [46]. The stealth liposomes induced a decrease in drug-associated hemolytic toxicity and
made the formulation safer and acceptable for parenteral administration.
3.9. AO/PI staining
To assess the antitumor potential of quercetin loaded liposomes in human cervical cancer cells, HeLa cells were treated with
quercetin, L1Q and L2Q, and AO/PI staining was performed. The AO/PI staining ratio indicates the ratio of the number of
viable cells to the number of dead cells. The decrease in the ratio accelerates the apoptosis of the cells (Figure 9a). The AO/
PI staining experiments showed a significant decrease (27% higher than the control level) in the quercetin treated HeLa
cells. Moreover, AO/PI staining level was decreased in L1Q and L2Q treated groups, with statistical significance (Figure
9b).
3.10. qPCR for gene expressions
To investigate the effects of quercetin loaded liposomes treatment on HeLa cell apoptosis, mitochondrial apoptotic gene
expression levels were measured such as Bax and Bcl-2. Bax is known as a proapoptotic gene while Bcl-2 is an antiapoptotic
gene. Our results showed that quercetin could not influence the mitochondrial apoptotic proteins as Bax. Bax gene
expression levels were increased in L1Q and L2Q treated groups compared to control (Figure 9c). On the other hand, Bcl2 gene expression levels were decreased in quercetin, L1Q and L2Q treated groups compare to control (Figure 9d). These
results suggest that the quercetin loaded liposomes treatment could trigger the mitochondrial apoptosis of HeLa cells.
4. Conclusion
In the present study, QC loaded PEG4000 modified liposomal formulations were successfully prepared in small size,
homogeneously dispersed and spherical shape. Their high encapsulation efficiency (87.6 ± 5.6%) was confirmed by two
different methods; centrifugation and dialysis. Cytotoxicity studies demonstrated that liposomal formulation of QC
inhibited the cell viability of cervical cancer. PEGylated liposomes remarkably decreased the IC value of free QC. The
number of colony diminished in the presence of liposomes, and the PEGylation decreased the colonization tendency of cells
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Figure 9. Apoptosis effects of quercetin loaded liposomes and quercetin loaded PEGylated liposomes compared to quercetin; A: cell
images after AO/PI staining; green emission refers to live cells while red emission refers to death cells, B: the ratio (%) of the number
of viable cells to the number of dead cells according to AO/PI staining, C: the values of Bax protein expressions after treatment and it
indicates the proapoptotic activity that induce apoptosis by forming mitochondrial permeability transition pores, D: the values of Bcl-2
protein expressions after treatment and its overexpression protects the cell against apoptosis.

to 85%. Formulations were found to be convenient to the parenteral application according to hemolysis assay. The AO/PI
staining study showed that the apoptosis of the cells was triggered with these developed nanoliposomal formulations. This
result was confirmed with protein expression studies by the occurrence of the increasing mitochondrial apoptotic gene
expression levels when cells exposed to the liposomal formulation. This result confirmed the increasing mitochondrial
apoptotic gene expression levels in cells exposed to liposomal formulations in protein expression studies. As a result of this
study, liposomes as well as PEG4000 increased the solubility of QC and the amount of QC required for therapeutic efficacy
could be significantly reduced with this promising drug delivery system.
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Highlights
· The solubility of quercetin can be increased by adding surfactant. PEG4000 increased quercetin solubility more
effectively than PEG2000.
· PEG4000 in liposomal formulation provided the convenience of liposomes for the parenteral application.
· The IC50 value of quercetin in HeLa cells remarkably decreased using PEG4000 modified liposomal quercetin.
· Developed liposomal quercetin at minimal doses induced mitochondrial apoptosis in HeLa cells much effectively
than free quercetin.
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